Related Experiment Video
Updated: Jun 23, 2026

05:58
Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
Published on: March 22, 2022
[Medical device registration system comparison between China and U.S.A]
1Shanghai Municipal Food and Drug Administration.
Summary
China's medical device registration system has design flaws in supervision and management compared to the U.S. Food and Drug Administration (FDA). This analysis identifies key issues and areas for improvement in China's regulatory framework.
Area of Science:
- Regulatory Science
- Medical Device Regulation
- Comparative Health Policy
Background:
- Medical device regulation is critical for patient safety and market access.
- Significant differences exist between China's and the U.S. FDA's medical device registration systems.
- Understanding these differences is crucial for international harmonization and improving regulatory efficiency.
Purpose of the Study:
- To compare China's medical device registration system with the U.S. FDA system.
- To identify design defaults and shortcomings in China's regulatory supervision and management.
- To analyze the core elements of substantial equivalence approval in medical device registration.
Main Methods:
- Comparative analysis of regulatory frameworks.
- Review of existing medical device registration policies in China and the U.S. FDA.
- Identification and analysis of design flaws in the Chinese system.
Main Results:
- The Chinese medical device registration system exhibits design defaults in its supervision and management.
- Key elements of substantial equivalence approval were analyzed within both regulatory systems.
- Specific areas needing improvement in China's medical device registration system were identified.
Conclusions:
- China's medical device regulatory system requires significant enhancements in supervision and management.
- Addressing identified design defaults is essential for improving the efficiency and effectiveness of medical device registration in China.
- The study provides critical insights for reforming China's medical device regulatory framework.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...